Abstergo Industries

Abstergo Industries, a multinational corporation, reported a successful year in genetic research in 2023, aiming for further developments in 2024. Specializing in the study and application of genetic data, Abstergo has made breakthroughs in areas like disease cure development and genetic traits identification. For 2024, they plan to enhance their genetic memory exploring device, the Animus, and expand their global data network, Eye-Abstergo....

Leading the Way in Genetic Research Abstergo Industries, a multinational corporation, reported a successful year in genetic research in 2023, aiming for further developments in 2024. Specializing in the study and application of genet…

Abstergo Industries is pioneering developments in cancer drug research, focusing on immunotherapy, targeted therapies, genetics of cancer, and prevention strategies. The company's primary concern is their newly developed cancer drug, Oncolux, a targeted therapy displaying promising results in preclinical trials for its capacity to destroy cancer cells without harming healthy ones. Abstergo aims to revolutionize the field, aspiring to improve patient lives and contribute significantly to future cancer research....

Research on cancer: Update Abstergo Industries is pioneering developments in cancer drug research, focusing on immunotherapy, targeted therapies, genetics of cancer, and prevention strategies. The company’s primary con…

Abstergo Industries is proud to announce our latest satellite program, the Akashic Satellite Plexus® 2.0. This program builds on the success of our previous satellite programs, including the original Akashic Satellite Plexus® launched in 2008 and the EYE-ABSTERGO® satellite launched in 2012. Our goal with this new program is to extend the reach and capabilities of our satellite network to improve the lives of people all over the world....

Abstergo Launches New Satellite Program to Improve Global Connectivity and Safety Abstergo Industries is proud to announce our latest satellite program, the Akashic Satellite Plexus® 2.0. This program builds on the success of our previous satellite programs, including the origin…

Abstergo Industries is dedicated to advancing the science of aging and developing treatments to slow the aging process. Aging is a complex process that involves a variety of biological pathways and mechanisms, including genetic, environmental, and lifestyle factors. Our research focuses on understanding these pathways and developing interventions that can target them to extend healthy lifespan. One area of research that holds great promise is the use of senolytic drugs....

Advancing the Science of Aging: Abstergo’s Research on Slowing the Aging Process Abstergo Industries is dedicated to advancing the science of aging and developing treatments to slow the aging process. Aging is a complex process that involves a variety of biological pathways and…

Abstergo Industries is excited to announce the development of a new pharmaceutical product that has the potential to revolutionize the treatment of a wide range of conditions. The new drug, which is currently in the early stages of clinical trials, targets a specific enzyme that plays a key role in a variety of physiological processes. By inhibiting the activity of this enzyme, the drug has shown promising results in the treatment of conditions such as inflammation, pain, and immune disorders....

Breakthrough: New Abstergo drug for a wide range of application scenarios Abstergo Industries is excited to announce the development of a new pharmaceutical product that has the potential to revolutionize the treatment of a wide range of conditions. The new drug, which i…

Abstergo Industries is excited to announce the upcoming release of the latest version of the a-OS, our proprietary operating system for the Animus. The new a-OS, known as a-OS 23, represents a major upgrade from previous versions and includes a number of exciting new features. One of the key improvements of a-OS 23 is its enhanced user interface, which has been redesigned to be even more intuitive and user-friendly....

New Animus Operating System a-OS Abstergo Industries is excited to announce the upcoming release of the latest version of the a-OS, our proprietary operating system for the Animus. The new a-OS, known as a-OS 23, represents a majo…

Abstergo Industries is proud to announce the latest iteration of the Animus, the revolutionary device that allows our researchers to experience the genetic memories of our test subject's ancestors. The Animus has been a key tool in our research into the field of genetic memory, and the new Animus represents a major step forward in this exciting area of study....

Genetic memories: Past, present and future of human behaviour Abstergo Industries is proud to announce the latest iteration of the Animus, the revolutionary device that allows our researchers to experience the genetic memories of our test subject’s ance…

Over the past two years, we have made significant progress in a number of key areas and wanted to take a moment to update you on our recent activities. As a global leader in the pharmaceutical, finance, and technology sectors, it is our responsibility to stay attuned to global developments and adapt accordingly. In light of the Covid-19 pandemic, we have made efforts to support research and healthcare organizations working to combat the virus....

Update on Abstergo’s current activities Over the past two years, we have made significant progress in a number of key areas and wanted to take a moment to update you on our recent activities. As a global leader in the pharmaceutical, fin…

Abstergo Pharmaceuticals was one of the first companies to conduct research on an active pharmaceutical substance against COVID-19. Since December 2019, we have made enormous progress. After the first tests on chimpanzees were successful in June, a test study on a small number of sick people was started in July. After this test was also successful, we were able to start a large-scale test with several thousand test subjects in September. [ 80 more words ]

Information about COVID-19 vaccination Abstergo Pharmaceuticals was one of the first companies to conduct research on an active pharmaceutical substance against COVID-19. Since December 2019, we have made enormous progress. After the fi…

See the trailer of the new Abstergo Entertainment Game: Valhalla

See the trailer of the new Abstergo Entertainment Game: Valhalla Visit the post for more.

No dragons. Maybe Ravens. The artwork is based on themes described on Abstergo.org.

See the making-of an artwork that will reveal the secret of our announcement

See the making-of an artwork that will reveal the secret of our announcement Visit the post for more.